Global Health · NSE: MEDANTA · BSE: 543654
Q3 FY23 results · Oct–Dec 2022
Global Health reported revenue from operations of ₹694.32 crore and net profit of ₹80.61 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 694.32 | — | — | — | — |
| Other income | 11.90 | — | — | — | — |
| Total income | 706.23 | — | — | — | — |
| Profit before tax | 112.45 | — | — | — | — |
| Net profit for the period | 80.61 | — | — | — | — |
| EPS, basic (₹) | 3.08 | — | — | — | — |
| Net margin (%) | 11.6 | — | — |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 489.79 | — | — | — | — |
| Other income | 12.52 | — | — | — | — |
| Total income | 502.31 | — | — | — | — |
| Profit before tax | 79.89 | — | — | — | — |
| Net profit for the period | 58.77 | — | — | — | — |
| EPS, basic (₹) | 2.25 | — | — | — | — |
| Net margin (%) | 12.0 | — | — |
Consolidated
- Filed with BSE
- 16 Feb 2023, 16:28 IST
- Board meeting
- 13 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 Feb 2023, 16:28 IST
- Board meeting
- 13 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE